Stryker Corporation 2002 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2002. Stryker Corporation develops, manufactures, and markets specialty surgical and medical products globally, including orthopaedic implants, trauma systems, spinal implants, and MedSurg equipment. The company also provides outpatient physical therapy services in the United States. Key 2002 developments included the acquisition of the Surgical Dynamics Inc. (SDI) spinal implant business and the DEKOMPRESSOR product line, as well as the commercial launch of the OP-1 bone growth factor in various markets.
Key Financial Metrics
| Metric | 2002 | 2001 |
|---|---|---|
| Net Sales | $3,011.6 million | $2,602.3 million |
| Gross Profit | $1,900.4 million (63.1% margin) | $1,638.5 million (63.0% margin) |
| Net Earnings | $345.6 million | $267.0 million |
| Diluted EPS | $1.70 | $1.32 |
| Operating Cash Flow | $503.9 million | $468.3 million |
| Total Debt | $501.7 million | $722.6 million |
| Working Capital | $443.8 million | $459.7 million |
| Cash & Equivalents | $37.8 million | $50.1 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16% to $3.01 billion, driven by an 18% increase in Orthopaedic Implants sales and a 13% increase in MedSurg Equipment sales. Growth was attributed to higher unit volumes, product mix changes, and acquisitions (SDI added $25.3 million in sales).
- Profitability: Net earnings rose 29% to $345.6 million. Adjusted net earnings (excluding nonrecurring items) increased 26% to $357.1 million.
- Restructuring Charges: The company recorded $17.2 million in restructuring and acquisition-related charges in 2002, primarily due to a $21.0 million charge for closing the Rutherford, New Jersey manufacturing facility. This contrasts with minimal charges in 2001.
- Debt Reduction: Total long-term debt decreased by $220.9 million to $501.7 million, reflecting significant repayments against credit facilities.
- Accounting Changes: Adoption of FASB Statement No. 142 eliminated goodwill amortization, which increased reported earnings compared to prior years where amortization was recorded.
Outlook, Risks, and Management Commentary
- Product Pipeline: Management highlighted the launch of the Trident Ceramic Acetabular Insert (FDA approved Feb 2003) and continued development of OP-1 for spinal indications. Clinical trials for OP-1 Putty in spine fusion are ongoing.
- Market Risks: The company faces risks from foreign currency fluctuations (exposed to Euro and Yen), regulatory actions affecting pricing and reimbursement, and competitive pressures in orthopaedics and MedSurg.
- Liquidity: Stryker maintains $589.8 million in available borrowing capacity under existing credit facilities. Management believes cash on hand and operating cash flows are sufficient to fund operations and debt repayments.
- Contingencies: The company is contingently liable for up to $42.5 million in milestone payments related to the DEKOMPRESSOR acquisition based on future sales growth.
Investor Verification Checklist
- Restructuring Costs: Verify the timeline and final cost of the Rutherford, NJ facility closure, as final severance payments are expected in 2004.
- OP-1 Commercialization: Monitor the progress of OP-1 clinical trials for spinal indications and the commercial uptake of the product under the Humanitarian Device Exemption (HDE).
- Acquisition Integration: Assess the integration performance of the Surgical Dynamics Inc. (SDI) spinal business and the realization of synergies.
- Foreign Currency Exposure: Review the impact of exchange rate fluctuations on international sales, which comprised 34% of total revenue.
- Debt Covenants: Confirm compliance with financial covenants under the $1,000 million unsecured credit facilities.